Evidence map›Paper›PMID 42326469›Full record

ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi-site before-and-after study.

Johannes C Michaelian, Azadeh Feizpour, James C Vickers, Jane E Alty, Jessica M Collins, Vincent Doré, Catriona Ireland, Anna E King, Ralph N Martins, Michael Woodward and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Johannes C MichaelianHealthy Brain Ageing Program, Brain and Mind Centre, School of Psychology, Faculty of Science University of Sydney Camperdown New South Wales Australia.ORCID https://orcid.org/0000-0001-5683-8222
Azadeh FeizpourFlorey Institute of Neuroscience and Mental Health Parkville Victoria Australia.
James C VickersWicking Dementia Research and Education Centre University of Tasmania Hobart Tasmania Australia.
Jane E AltyWicking Dementia Research and Education Centre University of Tasmania Hobart Tasmania Australia.
Jessica M CollinsWicking Dementia Research and Education Centre University of Tasmania Hobart Tasmania Australia.
Vincent DoréDepartment of Molecular Imaging & Therapy Austin Health Heidelberg Victoria Australia.
Catriona IrelandHealthy Brain Ageing Program, Brain and Mind Centre, School of Psychology, Faculty of Science University of Sydney Camperdown New South Wales Australia.
Anna E KingWicking Dementia Research and Education Centre University of Tasmania Hobart Tasmania Australia.
Ralph N MartinsMacquarie University Macquarie Park, New South Waless Australia.
Michael WoodwardDepartment of Continuing Care Austin Health Heidelberg Victoria Australia.
Sharon L NaismithHealthy Brain Ageing Program, Brain and Mind Centre, School of Psychology, Faculty of Science University of Sydney Camperdown New South Wales Australia.
Christopher C RoweFlorey Institute of Neuroscience and Mental Health Parkville Victoria Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRecent advances allow blood tests to detect key proteins linked to Alzheimer's disease (AD).

methodsIn this before-and-after study across three Australian memory and cognition clinics, we evaluated the impact on clinicians' diagnostic confidence and management following disclosure of routine patients' AD probability, using predefined plasma phosphorylated tau 181 (pTau181) thresholds set at 90% sensitivity and 90% specificity for amyloid-beta (Aβ) positron emission tomography (PET) positivity.

resultsOne hundred thirteen participants (mean age: 71.2 ± 8.4; mean Mini-Mental State Examination score: 27.7 ± 2.5) with dementia ( DISCUSSION: This study demonstrates the benefits of plasma pTau181 in real-world clinical practice particularly when diagnostic confidence is only low-to-moderate.

Indexed as

Alzheimer's diseaseblood‐based biomarkersdementiadiagnostic changemanagement change

Identifiers

PMID42326469
PMCPMC13279349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.